The launch follows the approval from the US Food and Drug Administration for Letrozole 2.5mg Tablets’ abbreviated new drug application (ANDA).
Letrozole tablets are bioequivalent to Novartis’ Femara, which contains 2.5mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis).
Femara tablets are approved for the adjuvant treatment of postmenopausal women with hormone receptor-positive early stage breast cancer.